Highlights from ASCO 2020: updates on the treatment of chronic lymphocytic leukemia

  • S. Dolan Dalhousie University
  • A. Christofides IMPACT Medicom Inc.
  • S. Doucette IMPACT Medicom Inc., University of Calgary
  • M. Shafey University of Calgary
Keywords: Chronic lymphocytic leukemia,, untreated disease, treatment-naïve disease, relapsed disease, refractory disease

Abstract

Because of the global coronavirus pandemic, the 2020 annual scientific meeting of the American Society of Clinical Oncology took place virtually 29–30 May. At the meeting, results from key studies about the treatment of chronic lymphocytic leukemia (cll) were disseminated. Studies examined the efficacy and safety of ibrutinib, acalabrutinib, zanubrutinib, and venetoclax as monotherapy or in combination with novel agents for patients with treatment-naïve and relapsed or refractory cll. Our meeting report describes the foregoing studies and presents interviews with investigators and commentaries by Canadian hematologists about potential effects on Canadian practice.


Published
2020-07-14
How to Cite
Dolan, S., Christofides, A., Doucette, S., & Shafey, M. (2020). Highlights from ASCO 2020: updates on the treatment of chronic lymphocytic leukemia. Current Oncology, 27(4). https://doi.org/10.3747/co.27.7009
Section
Meeting Report